This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Groudine, S. B. Articles by Roberts, K. Search for Related Content PubMed PubMed Citation Articles by Groudine, S. B. Articles by Roberts, K. Related Collections Pharmacology

---

ANESTHETIC PHARMACOLOGY

A Randomized, Dose-Finding, Phase II Study of the Selective Relaxant Binding Drug, Sugammadex, Capable of Safely Reversing Profound Rocuronium-Induced Neuromuscular Block

Scott B. Groudine, MD^*, Roy Soto, MD, Cynthia Lien, MD, David Drover, MD, and Kevin Roberts, MD^*

From the *Department of Anesthesiology, Albany Medical Center, Albany, New York; Health Sciences Center, Stony Brook University Hospital, Stony Brook, New York; Department of Anesthesiology, Weill Medical College of Cornell University/New York Presbyterian Hospital, New York, New York; and Department of Anesthesia, Stanford Medical Center, Stanford, California.

Address correspondence to Scott B. Groudine, MD, Department of Anesthesiology, Albany Medical Center, A -131, 47 New Scotland Ave, Albany, NY 12208-34798. Address e-mail to groudis{at}mail.amc.edu.

BACKGROUND: The reversal of a deep neuromuscular blockade remains a significant clinical problem. Sugammadex, a modified -cyclodextrin, encapsulates steroidal neuromuscular blocking drugs, promoting their rapid dissociation from nicotinic receptors. Sugammadex is the first drug that acts as a selective relaxant binding agent.

METHODS: We enrolled 50 patients into a Phase II dose-finding study of the efficacy and safety of sugammadex. Subjects, anesthetized with nitrous oxide and propofol, were randomized to one of two doses of rocuronium (0.6 or 1.2 mg/kg) and to one of five doses of sugammadex (0.5, 1.0, 2.0, 4.0, or 8.0 mg/kg). Neuromuscular monitoring was performed using the TOF Watch SX® acceleromyograph. Recovery was defined as a train-of-four ratio 0.9. Sugammadex was administered during profound block when neuromuscular monitoring demonstrated a posttetanic count of one or two.

RESULTS: Reversal of neuromuscular block was obtained after administration of sugammadex in all but the lowest dose groups (0.5–1.0 mg/kg) where several subjects could not be adequately reversed. At the 2 mg/kg dose all patients were reversed with sugammadex, but there was significant variability (1.8–15.2 min). Patient variability decreased and speed of recovery increased in a dose-dependent manner. At the highest dose (8 mg/kg), mean recovery time was 1.2 min (range 0.8–2.1 min). No serious adverse events were reported during this trial.

CONCLUSIONS: Sugammadex was well tolerated and effective in rapidly reversing profound rocuronium-induced neuromuscular block. The mean time to recovery decreased with increasing doses. Profound rocuronium-induced neuromuscular block can be reversed successfully with sugammadex at doses 2 mg/kg.

This article has been cited by other articles:

				P. F. White, B. Tufanogullari, O. Sacan, E. G. Pavlin, O. J. Viegas, H. S. Minkowitz, and M. E. Hudson The Effect of Residual Neuromuscular Blockade on the Speed of Reversal with Sugammadex Anesth. Analg., March 1, 2009; 108(3): 846 - 851. [Abstract] [Full Text] [PDF]

				E. A. Flockton, P. Mastronardi, J. M. Hunter, C. Gomar, R. K. Mirakhur, L. Aguilera, F. G. Giunta, C. Meistelman, and M. E. Prins Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine Br. J. Anaesth., May 1, 2008; 100(5): 622 - 630. [Abstract] [Full Text] [PDF]

				G. Cammu, P. J. De Kam, I. Demeyer, M. Decoopman, P. A. M. Peeters, J. M. W. Smeets, and L. Foubert Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers Br. J. Anaesth., March 1, 2008; 100(3): 373 - 379. [Abstract] [Full Text] [PDF]

				S. Groudine Sugammadex Rocuronium Dosing Anesth. Analg., September 1, 2007; 105(3): 884 - 884. [Full Text] [PDF]

				A. F. Kopman Sugammadex Rocuronium Dosing Anesth. Analg., September 1, 2007; 105(3): 883 - 884. [Full Text] [PDF]

				At Last: A Rapid Reversal Agent for Rocuronium Journal Watch Emergency Medicine, March 23, 2007; 2007(323): 2 - 2. [Full Text]

				R. D. Miller Sugammadex: An Opportunity to Change the Practice of Anesthesiology? Anesth. Analg., March 1, 2007; 104(3): 477 - 478. [Full Text] [PDF]